Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5]
Deferred
Reference number: GID-TA10905
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-July 2024 when we will write to you about how you can get involved.